Can erlotinib ameliorate cisplatin-induced toxicities?

Journal of Clinical Oncology

Volumn 31, Issue 27, 2013, Pages 3442-3443

  Sprowl, Jason A ^a   Mathijssen, Ron H ^b   Sparreboom, Alex ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ORGANIC CATION TRANSPORTER; PROTEIN TYROSINE KINASE INHIBITOR;

COCHLEA; HAIR CELL; HEAD AND NECK SQUAMOUS CELL CARCINOMA; KIDNEY TUBULE CELL; LETTER; LUNG NON SMALL CELL CANCER; NEPHROTOXICITY; NONHUMAN; ORTHOLOGY; OTOTOXICITY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SEVERE RENAL IMPAIRMENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE;

EID: 84893121613     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.8184     Document Type: Letter

References (15)

1. Martins RG, Parvathaneni U, Bauman JE, et al: Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized phase II trial. J Clin Oncol 31:1415-1421, 2013.
2. Vermorken JB, Trigo J, Hitt R, et al: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171-2177, 2007. (Pubitemid 46954639)
3. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008.
4. Hansen AR, Siu LL: Epidermal growth factor receptor targeting in head and neck cancer: Have we been just skimming the surface? J Clin Oncol 31:1381-1383, 2013.
5. Yao X, Panichpisal K, Kurtzman N, et al: Cisplatin nephrotoxicity: A review. Am J Med Sci 334:115-124, 2007. (Pubitemid 47262919)
6. Filipski KK, Mathijssen RH, Mikkelsen TS, et al: Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86:396-402, 2009.
7. Ciarimboli G, Deuster D, Knief A, et al: Organic cation transporter 2 mediates cisplatin-induced oto- And nephrotoxicity and is a target for protective interventions. Am J Pathol 176:1169-1180, 2010.
8. Iwata K, Aizawa K, Kamitsu S, et al: Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. Clin Exp Nephrol 16:843-851, 2012.
9. Zhang J, Zhou W: Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem Toxicol 50:2289-2293, 2012.
10. Franke RM, Kosloske AM, Lancaster CS, et al: Influence of Oct1/Oct2- deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D- glucosaminidase. Clin Cancer Res 16:4198-4206, 2010.
11. Katsuda H, Yamashita M, Katsura H, et al: Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol Pharm Bull 33:1867-1871, 2010.
12. Elmeliegy MA, Carcaboso AM, Tagen M, et al: Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 17:89-99, 2011.
13. Sprowl JA, van Doorn L, Hu S, et al: Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: Influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther doi: 10.1038/clpt.2013.145. [Epub ahead of print July 17, 2013].
14. Schellens JH, Ma J, Planting AS, et al: Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours Br J Cancer 73:1569-1575, 1996. (Pubitemid 26235386)
15. Mok TS, Wu YL, Yu CJ, et al: Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 27:5080-5087, 2009.